Outcomes According to MSKCC Risk Score with Focus on the
Intermediate-Risk Group in Metastatic Renal Cell Carcinoma
Patients Treated with First-Line Sunitinib: A Retrospective
Analysis of 2390 Patients

J 2020

Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients

FIALA, Ondrej, Jindrich FINEK, Alexandr POPRACH, Bohuslav MELICHAR, Jindrich KOPECKY et. al.

Základní údaje

Originální název

Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients

Autoři

FIALA, Ondrej (203 Česká republika, garant), Jindrich FINEK (203 Česká republika), Alexandr POPRACH (203 Česká republika, domácí), Bohuslav MELICHAR (203 Česká republika), Jindrich KOPECKY (203 Česká republika), Milada ZEMANOVA (203 Česká republika), Katerina KOPECKOVA (203 Česká republika), Tomas MLCOCH (203 Česká republika), Tomáš DOLEŽAL (203 Česká republika, domácí), Lenka CAPKOVA (203 Česká republika) a Tomas BUCHLER (203 Česká republika)

Vydání

Cancers, BASEL, MDPI, 2020, 2072-6694

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.639

Kód RIV

RIV/00216224:14110/20:00118607

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3390/cancers12040808

UT WoS

000535587400038

Klíčová slova anglicky

renal cell carcinoma; Memorial Sloan-Kettering Cancer Center risk; sunitinib; first line; outcome

Štítky

14110516, 14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 17. 7. 2020 10:45, Mgr. Tereza Miškechová

Anotace

V originále

Background: The Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation of the impact of the MSKCC score on the outcomes in mRCC patients treated with first-line sunitinib, with a focus on the intermediate-risk group. Methods: Clinical data from 2390 mRCC patients were analysed retrospectively. Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analysed according to the MSKCC risk score. Results: ORR, median PFS, and OS for patients with one risk factor were 26.7%, 10.1, and 28.2 months versus 18.7%, 6.2, and 16.2 months, respectively, for those with two risk factors (ORR: p = 0.001, PFS: p < 0.001, OS: p < 0.001). ORR, median PFS, and OS were 33.0%, 17.0, and 44.7 months versus 24.1%, 9.0, and 24.1 months versus 13.4%, 4.5, and 9.5 months in the favourable-, intermediate-, and poor-risk groups, respectively (ORR: p < 0.001, PFS: p < 0.001, OS: p < 0.001). Conclusions: The results of the present retrospective study demonstrate the suitability of the MSKCC model in mRCC patients treated with first-line sunitinib and suggest different outcomes between patients with one or two risk factors.

Návaznosti

NV19-08-00250, projekt VaV

Název: Proteotypová klasifikace renálního karcinomu ve vztahu k prognóze a terapeutické odpovědi

Investor: Ministerstvo zdravotnictví ČR, Proteotypová klasifikace renálního karcinomu ve vztahu k prognóze a terapeutické odpovědi

Citovat

FIALA, Ondrej, Jindrich FINEK, Alexandr POPRACH, Bohuslav MELICHAR, Jindrich KOPECKY, Milada ZEMANOVA, Katerina KOPECKOVA, Tomas MLCOCH, Tomáš DOLEŽAL, Lenka CAPKOVA a Tomas BUCHLER. Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients. Cancers. BASEL: MDPI, 2020, roč. 12, č. 4, s. 1-12. ISSN 2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers12040808.

@article{1670598,
   author = {Fiala, Ondrej and Finek, Jindrich and Poprach, Alexandr and Melichar, Bohuslav and Kopecky, Jindrich and Zemanova, Milada and Kopeckova, Katerina and Mlcoch, Tomas and Doležal, Tomáš and Capkova, Lenka and Buchler, Tomas},
   article_location = {BASEL},
   article_number = {4},
   doi = {http://dx.doi.org/10.3390/cancers12040808},
   keywords = {renal cell carcinoma; Memorial Sloan-Kettering Cancer Center risk; sunitinib; first line; outcome},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients},
   url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225945/},
   volume = {12},
   year = {2020}
}

TY  - JOUR
ID  - 1670598
AU  - Fiala, Ondrej - Finek, Jindrich - Poprach, Alexandr - Melichar, Bohuslav - Kopecky, Jindrich - Zemanova, Milada - Kopeckova, Katerina - Mlcoch, Tomas - Doležal, Tomáš - Capkova, Lenka - Buchler, Tomas
PY  - 2020
TI  - Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
JF  - Cancers
VL  - 12
IS  - 4
SP  - 1-12
EP  - 1-12
PB  - MDPI
SN  - 20726694
KW  - renal cell carcinoma
KW  - Memorial Sloan-Kettering Cancer Center risk
KW  - sunitinib
KW  - first line
KW  - outcome
UR  - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225945/
L2  - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225945/
N2  - Background: The Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation of the impact of the MSKCC score on the outcomes in mRCC patients treated with first-line sunitinib, with a focus on the intermediate-risk group. Methods: Clinical data from 2390 mRCC patients were analysed retrospectively. Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analysed according to the MSKCC risk score. Results: ORR, median PFS, and OS for patients with one risk factor were 26.7%, 10.1, and 28.2 months versus 18.7%, 6.2, and 16.2 months, respectively, for those with two risk factors (ORR: p = 0.001, PFS: p < 0.001, OS: p < 0.001). ORR, median PFS, and OS were 33.0%, 17.0, and 44.7 months versus 24.1%, 9.0, and 24.1 months versus 13.4%, 4.5, and 9.5 months in the favourable-, intermediate-, and poor-risk groups, respectively (ORR: p < 0.001, PFS: p < 0.001, OS: p < 0.001). Conclusions: The results of the present retrospective study demonstrate the suitability of the MSKCC model in mRCC patients treated with first-line sunitinib and suggest different outcomes between patients with one or two risk factors.
ER  -

FIALA, Ondrej, Jindrich FINEK, Alexandr POPRACH, Bohuslav MELICHAR, Jindrich KOPECKY, Milada ZEMANOVA, Katerina KOPECKOVA, Tomas MLCOCH, Tomáš DOLEŽAL, Lenka CAPKOVA a Tomas BUCHLER. Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients. \textit{Cancers}. BASEL: MDPI, 2020, roč.~12, č.~4, s.~1-12. ISSN~2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers12040808.

Podrobný výpis o publikaci